Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy

BJU International

Volumn 111, Issue 6, 2013, Pages 928-933

  Ochiai, Atsushi ^a   Okihara, Koji ^a   Kamoi, Kazumi ^a   Oikawa, Takehiro ^b   Shimazui, Toru ^b   Murayama, Shin Ichiro ^c   Tomita, Kyoichi ^c   Umekawa, Tohru ^d   Uemura, Hirotsugu ^d   Miki, Tsuneharu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^d KINKI UNIVERSITY   (Japan)

Author keywords

Japanese men; PCA3 urine assay; prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ONCOGENE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER GENE 3; PROSTATE VOLUME; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; UNNECESSARY PROCEDURE; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ASIAN CONTINENTAL ANCESTRY GROUP; BIOPSY; HUMANS; JAPAN; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84876895476     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11683.x     Document Type: Article

References (17)

1. Catalona WJ, Smith DS, Raliff TL, et al. Measurement of prostate -specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-1161
2. Thompson IM, Pauler DK, Goodman PJ, et al. Prevallence of prostate cancer among men with a prostate-specific antigen level< or =4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-2246
3. Babaian RJ, Kojima M, Ramirez EI, et al. Comparison analysis of prostate specific antigen and its indexes in the detection of prostate cancer. J Urol 1996; 156: 432-437
4. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer form benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542-1547
5. Catalona WJ, Southwick PC, Slawin KW, et al. Comparison of percent free PSA, PSA density and age specific PSA cutoffs for prostate cancer detection and staging. Urology 2000; 56: 255-260
6. Bussemakers MJG, Bokhoven AV, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975-5979
7. Groskopf J, Aubin SMJ, Deras IL, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006; 52: 1089-1095
8. Marks LS, Fradet Y, Deras IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007; 69: 532-535
9. Deras IL, Aubin SM, Blasé A, et al. PCA: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008; 179: 1587-1592
10. Haese A, Taille A, Poppel H, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeated biopsy. Eur Urol 2008; 54: 1081-1088
11. Ochiai A, Okihara K, Kamoi K, et al. Prostate cancer gene 3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy. Int J Urol 2011; 18: 200-205
12. Epstein JI, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extent of non palpable (stag T1c) prostate cancer. JAMA 1994; 271: 368-374
13. Chun FK, Taille ADL, Poppel HV, et al. Prostate cacner gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol 2009; 56: 659-668
14. Adam A, Engelbrecht MJ, Bornman MS, et al. The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting. BJU Int 2011; 108: 1728-1733
15. Aubin SMJ, Reid J, Sarno MJ, et al. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the Dutasteride REDUCE trial. J Urol 2010; 184: 1947-1952
16. Nakanishi H, Groskopf J, Fritsche HA, et al. PCA3 molecular urine assay correlates with prostate tumor volume: implication in selecting candidate for active surveillance. J Urol 2008; 179: 1804-1810
17. Ploussard G, Durand X, Xylinas E, et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol 2011; 59: 422-429